Medical Spa MD is a community of 28,000+ plastic surgeons, dermatologists, & aesthetic physicians practicing cosmetic medicine worldwide. FREE Medical Spa Deals for Clinicians

About   |   Advertise   |   Press   |   Contact

2nd MD - Boarded US physicians work from anywhere.
Medical Justice
Relentlessly protecting physicians from frivolous lawsuits.

More control of your income, career, and lifestyle as a physician.

Medical Spa MD is a world-wide physician community for clinicians in skin clinics, laser centers and medspas with thousands of physician members around the world. By using this site you agree to our terms of service and fine print.

« Medical Spa Phishing? | Main | Treating Possible Dermal Filler Complications »

Nabota: New Botox alternative to enter the US Market?

Nabota - New Botox to enter the US Market?If the FDA clears Nabota, a neuromodulator making its way to the US Market, it could become yet another Botox alternative fighting for market share?

The South Korean pharmaceutical company Daewoong is gearing up to become the newest manufacturer of a Botox alternative in the US market. Nabota, a botulinum toxin type A injectable neurotoxin, is cleared by several Asian and South American countries to use. For its market entry to the US, clinical trials are in process which could lead to an FDA approval.

Clinical trials

Currently there are two trials for NABOTA. One is for blepharospasm, and another for Crow’s feet. Literature comparing the efficacy of Botox, Dysport, and Xeomin are limited for Crow’s feet. Despite such, there have been studies about how effective these three neuromodulators are and were found effective by several researchers.


More botulinum toxin products mean more competition. Plastic surgery is common in South Korea, and beauty standards are high. Nabota could give Botox, Dysport, and Xeomin a run for their money if Nabota can deliver longer and better outcomes.

There are limited literature on the efficacy of Nabota. In one study comparing Botox, Daewoong's drug proved more effective. Other studies focused on NABOTA were for post-stroke upper limb spasticity (Nam et al., 2015), masseter reduction (Wanitphakdeedecha, 2016), and masseter muscle hypertrophy (No, 2015).

Its possible implication, once it is FDA approved, is the idea of using Nabota’s efficacy, which Botox and the others are unable to treat in the long term.

Differences with the Current Three

According to Dressler (2016), Nabota has a special purification process. No other information about the process has been disclosed. In a book by Seo (2017), the author tabulated a comparison of all the current botulinum toxin products. There are little to no significant differences with the current US neuromodulators.

So this raises the question of, would practices carry Nabota or would they stick with Botox and the others?

Reader Comments (2)

I'm thinking I'll just stick with the old Botox standby... Maybe Xeomin or Dysport but a new drug from Asia will have a way to go to disrupt the market. (In one of the other posts it mentioned that a study using Botox improving depression. Maybe that's a market they can pursue.)

More competition is always welcome if: It's effective. It costs less. We can charge the same price or more.
Check those 3 boxes and I'm happy.

06.17 | Unregistered CommenterCloisdr

PostPost a New Comment

Enter your information below to add a new comment.
Author Email (optional):
Author URL (optional):
Some HTML allowed: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <code> <em> <i> <strike> <strong>

Join Medical Spa MD

Medical Spa MD

A community of dermatologists, plastic surgeons, laser clinics, & skin clinics world wide.

Medical Spa MD is a world-wide community of physicians and clinicians practicing cosmetic medicine. Please read our Terms of Service, Advertising Terms and Privacy Policy.

Copyright © 2011. All rights reserved.